A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation

A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation

Abstract Tardive dyskinesia involves involuntary movements of body parts and is often observed in individuals taking antipsychotics for extended periods. Initial treatment strategies include reducing medication dosage, switching medications, or using drugs to suppress symptoms. One of the therapeuti...

Full description

Saved in:
Bibliographic Details
Main Authors: Miki Ishida, Ryuya Ichikawa, Katsuya Ohbuchi, Hiroaki Oizumi, Yuki Miyamoto, Junji Yamauchi
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Reserpine
Tetrabenazine
VMAT-2
Tardive dyskinesia
CRISPR-Cas13
Elongation
Online Access:https://doi.org/10.1038/s41598-025-97308-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-97308-5

Similar Items